Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
(2003).
Targeting vascular risk in patients with metabolic syndrome but without diabetes..
Metabolism. 54(8), 1065-74.
(2005). Dry cough as first manifestation of giant-cell arteritis..
J Am Geriatr Soc. 54(12), 1957-8.
(2006). Dyslipidaemia, hypercoagulability and the metabolic syndrome..
Curr Vasc Pharmacol. 4(3), 175-83.
(2006). Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study..
Curr Med Res Opin. 22(5), 873-83.
(2006). Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy..
J Diabetes Complications. 20(1), 1-7.
(2006). Should atenolol still be recommended as first-line therapy for primary hypertension?.
Hellenic J Cardiol. 47(5), 298-307.
(2006). Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?.
Expert Opin Pharmacother. 8(5), 529-35.
(2007). Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort..
Angiology. 58(6), 689-97.
(2007). Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?.
Curr Pharm Des. 13(2), 229-39.
(2007). Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients..
Lipids. 42(11), 999-1009.
(2007). Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?.
Expert Opin Pharmacother. 8(14), 2267-77.
(2007). Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study..
Nephrol Dial Transplant. 22(1), 118-27.
(2007). Endothelial function, arterial stiffness and lipid lowering drugs..
Expert Opin Ther Targets. 11(9), 1143-60.
(2007). Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels..
Curr Drug Targets. 8(3), 483-8.
(2007). PCI and stable coronary heart disease--COURAGE to change our minds?.
Curr Vasc Pharmacol. 5(3), 173-4.
(2007). Pheochromocytoma: an update on genetics and management..
Endocr Relat Cancer. 14(4), 935-56.
(2007). Prevalence of vascular disease in metabolic syndrome using three proposed definitions..
Int J Cardiol. 117(2), 204-10.
(2007). The role of endocannabinoid system blockade in the treatment of the metabolic syndrome..
J Clin Pharmacol. 47(5), 642-52.
(2007). The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?.
Expert Opin Ther Targets. 11(2), 191-205.
(2007). Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients..
Open Cardiovasc Med J. 1, 8-14.
(2007). Statins and regression of coronary atherosclerosis..
JAMA. 297(20), 2197; author reply 2197.
(2007). Statins and renal function. Is the compound and dose making a difference?.
Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
(2007). Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures..
Curr Drug Targets. 8(8), 942-51.
(2007). Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?.
Expert Opin Investig Drugs. 17(7), 969-72.
(2008).